Trypanosoma cruzi trans-sialidase antigens: immunodominance and diagnostic applications
Trends in Parasitology · 2026-05 · 42 (5) · 366-376
DOI: 10.1016/j.pt.2026.02.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Parasitology, 2026-05. Verfasst von Ryan J Marczak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Neuraminidase, Chagas Disease, Glycoproteins. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA. Electronic address: jeffrey.whitman@ucsf.edu.
Förderung
- NHLBI NIH HHS
- National Heart Lung and Blood Institute
Zitieren
APA
Marczak, R. J., Bern, C., & Whitman, J. D. (2026). Trypanosoma cruzi trans-sialidase antigens: immunodominance and diagnostic applications. Trends in Parasitology, 42(5), 366-376. https://doi.org/10.1016/j.pt.2026.02.010
Vancouver
Marczak RJ, Bern C, Whitman JD. Trypanosoma cruzi trans-sialidase antigens: immunodominance and diagnostic applications. Trends in Parasitology. 2026;42(5):366-376. doi:10.1016/j.pt.2026.02.010
BibTeX
@article{Marczak2026,
author = {Marczak, Ryan J and Bern, Caryn and Whitman, Jeffrey D},
title = {Trypanosoma cruzi trans-sialidase antigens: immunodominance and diagnostic applications},
journal = {Trends in Parasitology},
year = {2026},
volume = {42},
number = {5},
pages = {366--376},
doi = {10.1016/j.pt.2026.02.010}
}
EUVIMED